Here’s what you should know:
1. The FDA approved the first biosimilar, adalimumab-atto, in September 2016.
2. Cyltezo is approved to treat several diseases including: rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
3. Cyltezo is a tumor necrosis factor blocker.
4. Adverse events associated with adalimumab-atto include infections and malignancies. The most common events, however, are infections and injection-site reactions.
More articles on gastroenterology:
Florida jury finds gastroenterologist not liable in alleged ‘slapdash colonoscopy’ trial — 6 insights
Contaminated scopes used in 500+ patients at Buffalo VA
Renewed interest in gastroparesis research brings cure into focus
